What are the medications for treating ventricular tachycardia (VTach) storm?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications for VTach Storm

Amiodarone is the first-line medication for ventricular tachycardia storm, with an initial loading dose of 150 mg IV over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min maintenance. 1, 2

First-Line Pharmacological Management

Amiodarone

  • Initial dose: 150 mg IV over 10 minutes
  • Follow with: 1 mg/min infusion for 6 hours
  • Maintenance: 0.5 mg/min (720 mg/24 hours) 1, 2
  • For breakthrough episodes: Additional 150 mg supplemental infusions over 10 minutes 2
  • FDA-approved specifically for hemodynamically unstable VT refractory to other therapy 2
  • Efficacy: 63-78% response rate in patients with recurrent, refractory VT 3, 4

Beta-Blockers

  • Particularly effective for polymorphic VT storm 1
  • Metoprolol: 5 mg IV over 1-2 minutes, repeated as needed every 5 minutes to maximum 15 mg 5
  • Esmolol: Loading dose 500 mcg/kg over 1 minute, followed by infusion of 50 mcg/kg/min; can increase to maximum 300 mcg/kg/min 5
  • Essential for catecholaminergic polymorphic VT and VT associated with acute ischemia 5, 1

Second-Line Medications

Lidocaine

  • Particularly useful for ischemia-related VT 1
  • Dosing: 1.0-1.5 mg/kg IV bolus, supplemental boluses of 0.5-0.75 mg/kg every 5-10 minutes
  • Maintenance: 2-4 mg/min infusion 1
  • Less effective than amiodarone (27% vs 78% immediate termination rate) 4

Procainamide

  • Dosing: 20-50 mg/min until arrhythmia suppressed, hypotension occurs, QRS prolongs by 50%, or total dose of 17 mg/kg reached 5, 1
  • Alternative: 100 mg every 5 minutes until arrhythmia controlled 5
  • Caution: Avoid in patients with QT prolongation and heart failure 5
  • Monitor for hypotension and QT prolongation 1

Magnesium Sulfate

  • Particularly effective for torsades de pointes
  • Dosing: 8 mmol bolus followed by infusion 1
  • Consider for all forms of polymorphic VT

Special Considerations

For Specific VT Types:

  • Polymorphic VT/Torsades de Pointes:

    • Magnesium sulfate: First-line
    • Beta-blockers: For catecholaminergic polymorphic VT
    • Isoproterenol: For pause-dependent torsades (if no congenital LQTS) 1
    • Potassium repletion to 4.5-5 mmol/L 1
  • Ischemia-related VT:

    • Lidocaine: Preferred for acute ischemic settings
    • Urgent coronary revascularization when appropriate
  • Incessant VT/Electrical Storm:

    • Amiodarone + beta-blocker combination
    • Deep sedation may be necessary to reduce sympathetic tone
    • Consider urgent catheter ablation if medication fails 1

Monitoring During Treatment

  • Continuous cardiac monitoring is essential
  • Regular blood pressure assessment
  • Monitor for drug toxicity:
    • Amiodarone: Hypotension, bradycardia, phlebitis 5, 2
    • Procainamide: QT prolongation, hypotension 5, 1
    • Lidocaine: CNS toxicity at high doses

Important Cautions

  • Avoid calcium channel blockers for wide-complex tachycardias of unknown origin 1
  • Do not combine multiple AV nodal blocking agents with longer duration of action 1
  • Class IC antiarrhythmic drugs should not be used in patients with history of MI 1
  • Amiodarone concentrations >2 mg/mL should be administered via central venous catheter to avoid phlebitis 2
  • High-dose IV amiodarone can cause serious adverse events including hypotension (23%) and bradycardia (11%) 3

For VTach storm that is truly refractory to medical therapy, urgent catheter ablation is recommended as a definitive treatment, particularly for patients with scar-related heart disease 1.

References

Guideline

Management of Ventricular Tachycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.